Healthcare TechnologyGRAIL’s Galleri Test Heads to FDA Panel After Staff ReviewGRAIL Inc. (Nasdaq: GRAL) is scheduled to bring its Galleri multi-cancer blood test before a U.S. Food and Drug Administration advisory panel on September 23, 2026, following the release of…
FDA & Clinical TrialsOS Therapies Reports FDA Alignment on OST-HER2 Phase 3 Design
FDA & Clinical TrialsTML-6 Enters a Field Where Rival Drugs Are Already Approved
Biotech Market NewsTelix to Buy Radioisotope Giant ITM for $1.65 Billion
FDA & Clinical TrialsLongeveron Phase 2b Heart Trial Misses Primary Endpoint
FDA & Clinical TrialsUltragenyx Wins FDA Approval for Fayuvi in Sanfilippo Syndrome
FDA & Clinical TrialsSkyhawk’s SKY-0515 Holds Up at 15 Months in HD Trial
FDA & Clinical TrialsOptimi Health Plans Phase 3 MDMA Trial for PTSD
Healthcare TechnologyTelo Genomics Reports Higher MRD Detection in Myeloma Study
Healthcare TechnologyInside the Federal Review That Could Reshape Lab AI
FDA & Clinical TrialsZipalertinib Combo Halves Lung Cancer Progression Risk
FDA & Clinical Trials
Coverage of FDA decisions, drug approvals, trial results, regulatory updates, and major healthcare milestones affecting biotech companies.
View all →
Biotech Market News
Reporting on biotech stock activity, earnings, partnerships, financings, mergers, acquisitions, and market-moving developments.
View all →
Healthcare Technology
News and analysis covering medical technology, AI in healthcare, diagnostics, genomics, digital health, and emerging biotech innovation.
View all →
Pharmaceuticals
Coverage focused on drug development, treatments, vaccines, oncology, rare diseases, and advances in pharmaceutical research.
View all →
Industry & Research
Articles exploring scientific discoveries, biotechnology trends, academic research, manufacturing advances, and the broader biotech landscape.
View all →
